Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quinagolide - Ferring Pharmaceuticals/Novartis

Drug Profile

Quinagolide - Ferring Pharmaceuticals/Novartis

Alternative Names: CV 205 502; FE-999051; Norprolac; Quinagolide hydrochloride; SDS-205502; SDZ-205502

Latest Information Update: 10 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Ferring Pharmaceuticals; Novartis
  • Class Aminoquinolines; Analgesics; Infertility therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility; Hyperprolactinaemia; Prolactinoma
  • Phase II Adenomyosis; Endometriosis; Pain

Most Recent Events

  • 18 Jul 2021 Ferring Pharmaceuticals completes the phase II QLARITY trial for Endometriosis and Adenomyosis in Italy, Germany, Denmark and Poland (Vaginal) (NCT03749109)
  • 17 Sep 2020 Ferring Pharmaceuticals re-initiates enrolment in the phase II RQUEL trial for Pain in USA (Vaginal) (NCT03692403)
  • 12 Jun 2020 Ferring Pharmaceuticals re-initiates recruitment in the phase II QLARITY trial for Adenomyosis in Italy, Denmark, Poland and Germany (NCT03749109)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top